S&P 500   3,905.19 (-0.47%)
DOW   31,264.87 (-0.72%)
QQQ   290.32 (-0.28%)
AAPL   137.39 (-2.44%)
MSFT   253.27 (-0.32%)
FB   191.92 (-0.17%)
GOOGL   2,211.56 (-1.18%)
AMZN   2,157.13 (+0.69%)
TSLA   711.53 (+0.24%)
NVDA   172.47 (+1.82%)
BABA   88.18 (+1.00%)
NIO   16.68 (+5.37%)
AMD   97.82 (+1.60%)
CGC   5.87 (+5.01%)
MU   69.50 (-2.18%)
T   20.12 (-0.54%)
GE   75.52 (+0.43%)
F   12.90 (+0.94%)
DIS   103.29 (-0.97%)
AMC   12.77 (+0.08%)
PFE   50.27 (-0.26%)
PYPL   81.28 (+5.31%)
NFLX   184.51 (+4.13%)
S&P 500   3,905.19 (-0.47%)
DOW   31,264.87 (-0.72%)
QQQ   290.32 (-0.28%)
AAPL   137.39 (-2.44%)
MSFT   253.27 (-0.32%)
FB   191.92 (-0.17%)
GOOGL   2,211.56 (-1.18%)
AMZN   2,157.13 (+0.69%)
TSLA   711.53 (+0.24%)
NVDA   172.47 (+1.82%)
BABA   88.18 (+1.00%)
NIO   16.68 (+5.37%)
AMD   97.82 (+1.60%)
CGC   5.87 (+5.01%)
MU   69.50 (-2.18%)
T   20.12 (-0.54%)
GE   75.52 (+0.43%)
F   12.90 (+0.94%)
DIS   103.29 (-0.97%)
AMC   12.77 (+0.08%)
PFE   50.27 (-0.26%)
PYPL   81.28 (+5.31%)
NFLX   184.51 (+4.13%)
S&P 500   3,905.19 (-0.47%)
DOW   31,264.87 (-0.72%)
QQQ   290.32 (-0.28%)
AAPL   137.39 (-2.44%)
MSFT   253.27 (-0.32%)
FB   191.92 (-0.17%)
GOOGL   2,211.56 (-1.18%)
AMZN   2,157.13 (+0.69%)
TSLA   711.53 (+0.24%)
NVDA   172.47 (+1.82%)
BABA   88.18 (+1.00%)
NIO   16.68 (+5.37%)
AMD   97.82 (+1.60%)
CGC   5.87 (+5.01%)
MU   69.50 (-2.18%)
T   20.12 (-0.54%)
GE   75.52 (+0.43%)
F   12.90 (+0.94%)
DIS   103.29 (-0.97%)
AMC   12.77 (+0.08%)
PFE   50.27 (-0.26%)
PYPL   81.28 (+5.31%)
NFLX   184.51 (+4.13%)
S&P 500   3,905.19 (-0.47%)
DOW   31,264.87 (-0.72%)
QQQ   290.32 (-0.28%)
AAPL   137.39 (-2.44%)
MSFT   253.27 (-0.32%)
FB   191.92 (-0.17%)
GOOGL   2,211.56 (-1.18%)
AMZN   2,157.13 (+0.69%)
TSLA   711.53 (+0.24%)
NVDA   172.47 (+1.82%)
BABA   88.18 (+1.00%)
NIO   16.68 (+5.37%)
AMD   97.82 (+1.60%)
CGC   5.87 (+5.01%)
MU   69.50 (-2.18%)
T   20.12 (-0.54%)
GE   75.52 (+0.43%)
F   12.90 (+0.94%)
DIS   103.29 (-0.97%)
AMC   12.77 (+0.08%)
PFE   50.27 (-0.26%)
PYPL   81.28 (+5.31%)
NFLX   184.51 (+4.13%)
NASDAQ:ARGX

argenx Price Target, Predictions & Analyst Ratings

$315.13
+10.42 (+3.42%)
(As of 05/19/2022 01:13 PM ET)
Add
Compare
Today's Range
$309.78
$319.98
50-Day Range
$269.58
$328.77
52-Week Range
$249.50
$356.78
Volume
4,843 shs
Average Volume
395,488 shs
Market Capitalization
$16.90 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.11

argenx (NASDAQ:ARGX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Buy
Based on 18 Analyst Ratings

Analyst Price Target Consensus

$360.38
14.36% Upside

High PT$455.00
Average PT$360.38
Low PT$250.00
TypeCurrent
5/19/21 to 5/19/22
1 Month Ago
4/19/21 to 4/19/22
3 Months Ago
2/18/21 to 2/18/22
1 Year Ago
5/19/20 to 5/19/21
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
16 Buy rating(s)
14 Buy rating(s)
15 Buy rating(s)
10 Buy rating(s)
Hold
1 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
7 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$360.38$354.31$358.53$300.93
Price Target Upside14.36% Upside16.80% Upside15.52% Upside11.79% Upside
Get argenx Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

argenx (NASDAQ:ARGX) vs. Its Competitors

TypeargenxMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.52
Consensus RatingBuyBuyBuy
Price Target Upside18.27% Upside462.91% Upside29.34% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
543
67.04%
Underperform Votes
267
32.96%
Avg. Outperform Votes
171
67.32%
Avg. Underperform Votes
83
32.68%
Avg. Outperform Votes
839
69.34%
Avg. Underperform Votes
371
30.66%

argenx (NASDAQ:ARGX) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/13/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
5/6/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetOverweight ➝ Overweight€350.00 ➝ €370.00
5/3/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight$375.00+27.83%
3/4/2022HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Douglas Tsao
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$400.00+48.72%
12/21/2021Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetBuy ➝ Buy$350.00 ➝ $365.00+6.03%
12/21/2021JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetMarket Outperform$368.00 ➝ $418.00+23.85%
12/20/2021Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetOverweight$390.00 ➝ $395.00+27.31%
12/20/2021Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetNeutral$297.00 ➝ $340.00+9.59%
12/20/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetStrong-Buy$390.00 ➝ $455.00+46.65%
12/2/2021Kepler Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Damien Choplain
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$220.00 ➝ $290.00-0.60%
11/29/2021Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight$250.00 ➝ $354.00+28.21%
10/28/2021Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$330.00+17.51%
10/19/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeEqual Weight ➝ Overweight
10/6/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$362.00+23.42%
10/4/2021Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetOutperform$333.00 ➝ $355.00+17.21%
9/23/2021Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Charles Pitman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$205.00 ➝ $325.00+4.65%
7/22/2021Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetOutperform$344.00 ➝ $362.00+13.48%
6/18/2021UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$390.00+23.84%
2/18/2021Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetOutperform$317.00 ➝ $430.00+16.01%
10/6/2020Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetBuy$265.00 ➝ $298.00+10.71%
7/30/2020Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Derek Archila
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$253.00+6.51%
5/27/2020SunTrust Banks
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetBuy$192.00 ➝ $240.00+13.14%
5/17/2020Nomura
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$255.00+62.59%
3/4/2020Nomura Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$255.00+73.05%
1/6/2020Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetOverweight$177.00 ➝ $194.00+22.34%
10/31/2019William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform
(Data available from 5/19/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












argenx (NASDAQ:ARGX) Analyst Ratings Frequently Asked Questions

What is argenx's consensus rating and price target?

According to the issued ratings of 18 analysts in the last year, the consensus rating for argenx stock is Buy based on the current 1 hold rating, 16 buy ratings and 1 strong buy rating for ARGX. The average twelve-month price target for argenx is $360.38 with a high price target of $455.00 and a low price target of $250.00. Learn more on ARGX's analyst rating history.

Do Wall Street analysts like argenx more than its competitors?

Analysts like argenx stock more than the stock of other Medical companies. The consensus rating score for argenx is 3.00 while the average consensus rating score for medical companies is 2.72. Learn more on how ARGX compares to other companies.

Do MarketBeat users like argenx more than its competitors?

MarketBeat users like argenx stock less than the stock of other Medical companies. 67.04% of MarketBeat users gave argenx an outperform vote while medical companies recieve an average of 67.32% outperform votes by MarketBeat users.

Is argenx being upgraded by Wall Street analysts?

Over the previous 90 days, argenx's stock had 2 upgrades by analysts.

Does argenx's stock price have much upside?

According to analysts, argenx's stock has a predicted upside of 18.14% based on their 12-month price targets.

What analysts cover argenx?

argenx has been rated by Deutsche Bank Aktiengesellschaft, HC Wainwright, JPMorgan Chase & Co., and Morgan Stanley in the past 90 days.

This page was last updated on 5/19/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.